IndraLab

"23 A study using an oncogenic cell line (E1A cells) found that USP18 activates the extrinsic TNF-related apoptosis-inducing ligand (TRAIL) pathway after IFN-α challenge."

"Indeed, it has been shown that ablating USP18, the enzyme that deconjugates ISG15 from target proteins, increased TRAIL production and promoted the extrinsic apoptosis pathway in cells treated with IF[MISSING/INVALID CREDENTIALS: limited to 200 char for Elsevier]"

"23 A study using an oncogenic cell line (E1A cells) found that USP18 activates the extrinsic TNF related apoptosis inducing ligand (TRAIL) pathway after IFN-alpha challenge."

"Treating Usp18 -deficient hematopoietic cells with Poly I:C decreases the number of white blood cells since apoptosis is not prevented by USP18. xref Moreover, knocking down USP18 markedly enhances the NF- κ B signaling induced by various TLR ligands. xref A study using an oncogenic cell line (E1A cells) found that USP18 activates the extrinsic TNF-related apoptosis-inducing ligand (TRAIL) pathway after IFN- α challenge. xref In human promonocytic THP-1 cells, the expression of proinflammatory cytokines such as TNF- α , interleukin-6 (IL-6), and IL-1 β is significantly higher when USP18 is silenced with siRNA. xref Interestingly, in contrast to E1A cells, Usp18 -deficient murine bone marrow cells and THP-1 cells that have been treated with IFN α / β do not experience apoptosis after treatment with TRAIL or FASL. xref However, IFN- α / β still triggers apoptosis in these cells through the mitochondrial pathway and the reactive oxygen species pathway, xref a finding indicating that USP18 influences cell survival in various pathways depending on the cell type."